What is special about the Diapat test?
It is the world's first clinically validated molecular disease detection that can detect early and precisely, in particular, chronic diseases that have not been discovered for many years.
What is so important about molecular detection?
All of the chronic diseases, especially cardiovascular, kidney, liver, and lung diseases, arise and exist only on a molecular level. However, the previous diagnostics only determine the advanced loss of the organ function.
How does this benefit the patient?
Drugs only work at the molecular level, on the proteome level. If the diseases are detected too late when the organs are already irreparably damaged, the drugs cannot develop their potential. Only the early and accurate detection of the disease-related cellular change enables the chronic disease to be stopped in good time and preserves organ function as well as the body's own defenses, e.g. against SARS-CoV.-2 or other virus-causing pandemics.
- DiaPat-CoV-50 Test shows in the partial result of the CRIT-COV study 0-2 days after Covid-19 diagnosis with an accuracy over 90% the three complication phases - light - severe - very difficult. Clinics want to use the test as urgently necessary ... [more]
The diagnosis of diabetic kidney disease with the DiaPat® DN-PROteom test is improved by 398% (!!!) and detects earlier compared to the currently used diagnostics. With the disruptive new drug of SGLT2 inhibitors, the diagnostic-therapeutic symbiosis is established. (Rossing et al. - Lancet D&E, 2020)
Note on the assumption of costs: The Federal Joint Committee does not want to decide on remuneration by the statutory health insurance until the end of 2021.
If the bile duct findings are unclear before a liver transplant is required, the contraindicating carcinoma must be determined. The DiaPat® BPA-CC + UPA-CC combination test increases the sensitivity of carcinoma detection from currently 50% to more than 90% and, if used in time, enables surgical removal of the carcinoma, preserves the transplant and life.
Comment on the assumption of costs: The Federal Joint Committee insists on a study after transplantation, which cannot be carried out due to a lack of ethics approval!